Wall Street brokerages expect PRA Health Sciences Inc (NASDAQ:PRAH) to post earnings of $1.03 per share for the current quarter, Zacks reports. Seven analysts have issued estimates for PRA Health Sciences’ earnings. The highest EPS estimate is $1.04 and the lowest is $1.01. PRA Health Sciences reported earnings per share of $0.71 in the same quarter last year, which indicates a positive year over year growth rate of 45.1%. The business is scheduled to announce its next earnings results on Wednesday, February 28th.

On average, analysts expect that PRA Health Sciences will report full-year earnings of $3.31 per share for the current fiscal year, with EPS estimates ranging from $3.30 to $3.32. For the next financial year, analysts forecast that the company will post earnings of $4.03 per share, with EPS estimates ranging from $3.80 to $4.18. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for PRA Health Sciences.

PRA Health Sciences (NASDAQ:PRAH) last posted its earnings results on Wednesday, October 25th. The medical research company reported $0.88 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.85 by $0.03. The company had revenue of $494.55 million during the quarter, compared to analysts’ expectations of $477.89 million. PRA Health Sciences had a net margin of 5.64% and a return on equity of 21.66%. PRA Health Sciences’s quarterly revenue was up 23.7% on a year-over-year basis. During the same period last year, the company posted $0.64 earnings per share.

PRAH has been the subject of several research analyst reports. Zacks Investment Research raised shares of PRA Health Sciences from a “hold” rating to a “buy” rating and set a $85.00 target price for the company in a research note on Wednesday, August 30th. SunTrust Banks reissued a “buy” rating and issued a $101.00 price objective on shares of PRA Health Sciences in a research note on Friday, October 27th. Jefferies Group reissued a “buy” rating and issued a $95.00 price objective on shares of PRA Health Sciences in a research note on Thursday, October 26th. Credit Suisse Group lifted their price objective on shares of PRA Health Sciences from $90.00 to $93.00 and gave the stock an “outperform” rating in a research note on Thursday, October 26th. Finally, KeyCorp reissued a “buy” rating and issued a $93.00 price objective (up from $86.00) on shares of PRA Health Sciences in a research note on Monday, October 30th. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $90.46.

In other PRA Health Sciences news, Director Matthew P. Young sold 5,115 shares of PRA Health Sciences stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $79.90, for a total value of $408,688.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 2.10% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. Renaissance Group LLC increased its stake in PRA Health Sciences by 2.5% in the second quarter. Renaissance Group LLC now owns 5,239 shares of the medical research company’s stock valued at $393,000 after purchasing an additional 126 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. increased its position in PRA Health Sciences by 1.9% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 8,505 shares of the medical research company’s stock worth $638,000 after purchasing an additional 160 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in PRA Health Sciences by 12.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock worth $112,000 after purchasing an additional 160 shares during the last quarter. Zacks Investment Management increased its position in PRA Health Sciences by 1.3% in the 2nd quarter. Zacks Investment Management now owns 48,885 shares of the medical research company’s stock worth $3,667,000 after purchasing an additional 614 shares during the last quarter. Finally, Sei Investments Co. increased its position in PRA Health Sciences by 4.9% in the 2nd quarter. Sei Investments Co. now owns 14,654 shares of the medical research company’s stock worth $1,100,000 after purchasing an additional 690 shares during the last quarter. Hedge funds and other institutional investors own 98.49% of the company’s stock.

PRA Health Sciences (PRAH) traded up $1.90 on Friday, reaching $89.13. 1,512,200 shares of the company traded hands, compared to its average volume of 532,122. The stock has a market capitalization of $5,527.74, a PE ratio of 32.07, a price-to-earnings-growth ratio of 1.51 and a beta of 0.40. PRA Health Sciences has a 52 week low of $53.47 and a 52 week high of $89.81. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 1.38.

ILLEGAL ACTIVITY NOTICE: This report was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/12/15/1-03-eps-expected-for-pra-health-sciences-inc-prah-this-quarter.html.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Get a free copy of the Zacks research report on PRA Health Sciences (PRAH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.